[go: up one dir, main page]

PE20001598A1 - DERIVATIVES OF N- [2- (4-AMINOPHENIL) ETHYL] -2,3-DIHYDRO-1,4-BENZODIOXIN-2-METANAMINA - Google Patents

DERIVATIVES OF N- [2- (4-AMINOPHENIL) ETHYL] -2,3-DIHYDRO-1,4-BENZODIOXIN-2-METANAMINA

Info

Publication number
PE20001598A1
PE20001598A1 PE2000000275A PE0002752000A PE20001598A1 PE 20001598 A1 PE20001598 A1 PE 20001598A1 PE 2000000275 A PE2000000275 A PE 2000000275A PE 0002752000 A PE0002752000 A PE 0002752000A PE 20001598 A1 PE20001598 A1 PE 20001598A1
Authority
PE
Peru
Prior art keywords
benzodioxin
dihydro
derivatives
ethyl
alcoxycarbonylmethyl
Prior art date
Application number
PE2000000275A
Other languages
Spanish (es)
Inventor
Yannick Evanno
Peretti Daniele De
Jean Francois Gibert
Michel Peynot
Maria Carmen Renones
Jocelyne Roy
Garcia Antonio Almario
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of PE20001598A1 publication Critical patent/PE20001598A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE N-[2-(4-AMINOFENIL)ETIL]-2,3-DIHIDRO-1,4-BENZODIOXIN-2-METANAMINA DE FORMULA I, DONDE: X ES H, HALOGENO, CIANO, NITRO, OH, ALQUILO C1-C4, FENILO, TIENILO, TIENILMETOXI, ALCOXI C1-C4, CICLOALQUILMETOXI C3-C6, FENILMETOXI, ALCOXICARBONILO C1-C4, ALCOXICARBONILMETILO C1-C4, PIRROLIDIN-1-ILCARBONILO, CARBAMOILO, ENTRE OTROS; R1 ES H, METILO; R2 ES ALCANOILO C1-C4, FENILALCANOILO C1-C4, METOXIACETILO, CICLOALQUILCARBONILO C3-C6, BENZOILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS; NR1R2 ES 2-OXO-4,5-DIHIDROOXAZOLIDIN-3-ILO. LOS COMPUESTOS DE FORMULA I TIENEN AFINIDAD POR LOS RECEPTORES DOPAMINERGICOS DE TIPO D3, AFINIDAD MODERADA DE TIPO D2 Y 5-HT1A Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE PSICOSIS, ESQUIZOFRENIA, ANSIEDAD, PANICO, FOBIAS, TRASTORNOS OBSESIVO COMPULSIVOSREFERS TO DERIVATIVES OF N- [2- (4-AMINOPHENYL) ETHYL] -2,3-DIHYDRO-1,4-BENZODIOXIN-2-METHANAMINE OF FORMULA I, WHERE: X IS H, HALOGEN, CYANE, NITRO, OH , C1-C4 ALKYL, PHENYL, THENYL, THYENYLMETOXY, C1-C4 ALCOXY, C3-C6 CYCLOALKYLMETOXY, PHENYLMETOXY, C1-C4 ALCOXYCARBONYL, 1-CARBONYL ALCOXYCARBONYLMETHYL-ILCHRONYL, C1-C4 CARBONYL-1-PYRAMYL-ILCOXYCARBONYL, C1-C4, ALCOXYCARBONYLMETHYL-ILCHYL-C4 R1 IS H, METHYL; R2 IS C1-C4 ALKANOYL, C1-C4 PHENYLALKANOYL, METOXYACETYL, C3-C6 CYCLOALKYLCARBONYL, BENZOYL OPTIONALLY SUBSTITUTED WITH HALOGEN, C1-C4 ALKYL, C1-C4 ALCOXY, AMONG OTHERS; NR1R2 IS 2-OXO-4,5-DIHYDROOXAZOLIDIN-3-ILO. THE COMPOUNDS OF FORMULA I HAVE AFFINITY FOR TYPE D3 DOPAMINERGIC RECEPTORS, MODERATE AFFINITY OF TYPE D2 AND 5-HT1A AND MAY BE USEFUL FOR THE TREATMENT OF PSYCHOSIS, SCHIZOPHRENIA, ANXIETY, PANIC, PHOBOSIVE, OBSESSIVE DISORDERS

PE2000000275A 1999-03-30 2000-03-30 DERIVATIVES OF N- [2- (4-AMINOPHENIL) ETHYL] -2,3-DIHYDRO-1,4-BENZODIOXIN-2-METANAMINA PE20001598A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903936A FR2791675B1 (en) 1999-03-30 1999-03-30 DERIVATIVES OF N- [2- (4-AMINOPHENYL) ETHYL] -2,3-DIHYDRO-1,4- BENZODIOXINNE-2-METHANAMINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Publications (1)

Publication Number Publication Date
PE20001598A1 true PE20001598A1 (en) 2001-04-01

Family

ID=9543788

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000275A PE20001598A1 (en) 1999-03-30 2000-03-30 DERIVATIVES OF N- [2- (4-AMINOPHENIL) ETHYL] -2,3-DIHYDRO-1,4-BENZODIOXIN-2-METANAMINA

Country Status (6)

Country Link
AU (1) AU3660700A (en)
CO (1) CO5170535A1 (en)
FR (1) FR2791675B1 (en)
PE (1) PE20001598A1 (en)
UY (1) UY26085A1 (en)
WO (1) WO2000058301A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7297704B2 (en) 2005-02-17 2007-11-20 Wyeth Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives
TW200720266A (en) * 2005-04-22 2007-06-01 Wyeth Corp Benzodioxane and benzodioxolan derivatives and uses thereof
JP2008538576A (en) 2005-04-22 2008-10-30 ワイス Chroman and chromene derivatives and uses thereof
AR060493A1 (en) * 2006-04-18 2008-06-18 Wyeth Corp DERIVATIVES OF BENZODIOXAN AND BENZODIOXOLAN. OBTAINING PROCESSES.
AR063373A1 (en) * 2006-10-24 2009-01-21 Wyeth Corp DERIVATIVES OF BENZODIOXAN AND ITS USES
WO2009133110A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
CN102036976B (en) 2008-04-29 2013-05-01 Nsab神经研究瑞典公司分公司 Modulators of dopamine neurotransmission
JP2011519839A (en) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ Modulator of dopamine neurotransmission
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281245A (en) * 1962-07-20
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives

Also Published As

Publication number Publication date
UY26085A1 (en) 2000-10-31
WO2000058301A1 (en) 2000-10-05
FR2791675B1 (en) 2001-05-04
FR2791675A1 (en) 2000-10-06
AU3660700A (en) 2000-10-16
CO5170535A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
PE20001598A1 (en) DERIVATIVES OF N- [2- (4-AMINOPHENIL) ETHYL] -2,3-DIHYDRO-1,4-BENZODIOXIN-2-METANAMINA
PE68799A1 (en) TETRAHYDROISOKINOLINE DERIVATIVES AS DOPAMINE D3 RECEPTOR MODULATORS
PE20001088A1 (en) TETRAHIDROBENZAZEPINE DERIVATIVE COMPOUNDS
PE20040600A1 (en) TRIAZOLE DERIVATIVES AS ANTAGONISTS OF THE TACHYCININ RECEPTOR
PE20031011A1 (en) DERIVATIVES OF DIHIDROBENZODIAZEPIN-2-ONA-III
PE20060010A1 (en) 2,3,4,5-TETRAHYDRO-1H-BENZO [d] 6-SUBSTITUTED AZEPINES AS AGONISTS OF THE 5-HT2C RECEPTOR
PE20010543A1 (en) PURINE DERIVATIVES AS TYROSINCINASE SYK INHIBITORS
PE20061150A1 (en) DERIVATIVES OF N- (N-SULFONYLAMINOARILMETIL) CYCLOPROPANOCARBOXAMIDE SUBSTITUTED AS ANTAGONISTS OF THE VAINILLOID RECEPTOR TYPE 1 (VDR1)
PE20030238A1 (en) USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BRAIN, SPINAL AND NEURONAL INJURIES
PE20001483A1 (en) OXAMIC ACIDS AND DERIVATIVES AS LIGANDS OF THYROID RECEPTORS
PE20011114A1 (en) DECAHYDRO-ISOQUINOLINS
AR054021A1 (en) CYCLOPENTAPIRIDINE AND TETRAHYDROQUINOLINE DERIVATIVES
PE20061298A1 (en) DIHYDROBENZOFURAN-DERIVED COMPOUNDS AS AGONISTS OF THE SEROTONIN 5-HT2C RECEPTOR
PE20081316A1 (en) HETEROCYCLIC COMPOUNDS THAT MODULATE THE ACTIVITY OF STEROIL-CoA-DESATURASE
PT98168A (en) METHOD FOR PREPARING NEW INDOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA200600348A1 (en) NEW CONNECTIONS
PE20061163A1 (en) SUBSTITUTE N-SULFONYLAMINOPHENYLETHYL-2-PHENOXYACETAMIDE COMPOUNDS
PE20050145A1 (en) DIHYDROQUINAZOLINES SUBSTITUTE AS ANTIVIRAL AGENTS
PE20040907A1 (en) ANILINOPYRAZOLE DERIVATIVES
PE20081504A1 (en) REPLACED BICYCLOCARBOXIAMIDE COMPOUNDS
PE20081496A1 (en) DERIVATIVES OF 2,5-DIHIDRO-3-H-PIRAZOLO [4,3-C] PIRIDAZIN-3-ONA SUBSTITUTED AS ANTAGONISTS OF CB1 RECEPTORS
PE20030610A1 (en) DERIVATIVES OF 3-AZABICYCLO [3.1.0] HEXANE WITH AFFINITY TO OPIOID RECEPTORS
PE20030541A1 (en) ALKYNATED FUSED RING PYRIMIDINE COMPOUNDS AS TYPE 13 MATRIX METALOPROTEASE INHIBITORS
PE20081833A1 (en) SPIRO-PIPERIDINE DERIVATIVES
PE20001461A1 (en) COMPOUNDS DERIVED FROM 3,16-DIHIDROXI-ESTRA-1,3,5 (10) -TRIENO, USE OF THE SAME AND OF STRUCTURAL PARTS OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed